ArticleThe Journal of antimicrobial chemotherapy2026
Metallo-β-lactamase-producing Enterobacterales: cyanide-containing efflux pump inhibitors as potential dual-activity inhibitors.
Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
BACKGROUND AND
objectivesMetallo-β-lactamase (MBL)-producing Enterobacterales represent a major public health threat because they confer resistance to all β-lactams except monobactams. The most prevalent MBLs include VIM, IMP, and NDM types, which render all clinically approved β-lactamase inhibitors ineffective. This study evaluates whether cyanide-containing molecules such as the efflux pump inhibitors carbonyl cyanide m-chlorophenylhydrazone (CCCP), carbonyl cyanide 4-trifluoromethoxyphenylhydrazone (FCCP) or the cytochrome C oxidase inhibitor potassium cyanide (KCN) can restore carbapenem susceptibility in MBL-producing strains by disrupting zinc-dependent enzymatic activity.
methodsA series of isogenic Escherichia coli TOP10 and MG1655 strains carrying the shuttle vector pUCP24 harbouring various MBLs and clinical strains were included in this study. The strains were subjected to antimicrobial susceptibility testing by broth microdilution, checkerboard assays, determination of the 50% inhibitory concentration (IC50) of carbapenemase activity, kinetic assays and time-kill curve assays.
resultsCCCP, FCCP and KCN restored carbapenem (imipenem) susceptibility in E. coli strains producing VIM-1-like enzymes. Synergy was observed in checkerboard assays, and reduction of bacterial growth was confirmed by time-kill experiments. The addition of Zn2+ reversed this effect, supporting a Zn2+-chelating or Zn2+-displacing mechanism. Non-VIM-1-like MBLs, including VIM-2, IMP-1 and NDM-1, were not affected by the addition of cyanide-containing compounds, indicating strong selectivity of these inhibitory effects. IC50 measurements confirmed the selective activity of CCCP, FCCP and KCN against VIM-1-like MBLs.
conclusionsCCCP, FCCP and KCN exhibited inhibitory activity against VIM-1-like MBLs, restoring imipenem susceptibility in E. coli at very low concentrations (0.04-19.55 µM). Thus, certain efflux pump inhibitors, as well as the gaseous biological mediator cyanide, have a novel action as inhibitors of MBL enzymatic activity, which, in turn, renders them potentially useful as adjunct antibacterial agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.